Advertisement
Screener

COMPASS PATHWAYS PLC (CMPS) EBITDA

COMPASS PATHWAYS PLC (CMPS) EBITDA

  • 2026-06-30: Basis Reported; EBITDA (m); Operating income -$52.37M; Depreciation and amortization (m).
  • 2026-03-31: Basis Reported; EBITDA (m); Operating income -$42.90M; Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA (m); Operating income -$40.54M; Depreciation and amortization (m).
  • 2025-06-30: Basis Reported; EBITDA (m); Operating income -$42.93M; Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history
2019-12-31 to 2024-03-31
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported(m)-$52.37M(m)(m)(m)(m)-$40.31M*(m)$29.18M(m)$331.00K
2026-03-31Reported(m)-$42.90M(m)(m)(m)(m)-$47.94M(m)$26.48M(m)-$11.00K
2025-09-30Reported(m)-$40.54M(m)(m)(m)(m)-$35.11M*(m)$27.32M(m)-$230.00K
2025-06-30Reported(m)-$42.93M(m)(m)(m)(m)-$38.69M*(m)$30.32M(m)$137.00K
2025-03-31Reported(m)-$49.62M(m)(m)(m)(m)-$45.66M(m)$30.88M(m)$354.00K
2024-09-30Reported-$47.84M*-$47.90M$59.00K*(m)(m)$0.00*-$22.18M*(m)$32.93M(m)$173.00K
2024-06-30Reported-$43.26M*-$43.32M$63.00K*(m)(m)$0.00*-$34.42M*(m)$29.07M(m)$176.00K
2024-03-31Reported-$38.51M(m)(m)(m)(m)$0.00-$20.83M(m)$24.90M(m)$222.00K
2023-12-31Reported-$38.51M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2023-09-30Reported-$33.88M*-$34.06M$186.00K*(m)(m)$18.00K*-$17.06M*(m)$21.53M(m)$62.00K
2023-06-30Reported-$32.55M*-$32.66M$110.00K*(m)(m)$19.00K*-$24.81M*(m)$19.82M(m)$194.00K
2023-03-31Reported-$31.74M(m)(m)(m)(m)$29.00K-$27.72M(m)$19.04M(m)$130.00K
2022-12-31Reported-$32.1M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2022-09-30Reported-$25.44M(m)(m)(m)(m)-$5.00K*-$19.02M*(m)$13.98M(m)$120.00K
2022-06-30Reported-$27.16M(m)(m)(m)(m)$412.00K*-$18.00M*(m)$15.92M(m)$56.00K
2022-03-31Reported-$25.37M(m)(m)(m)(m)$82.00K-$23.12M(m)$15.36M(m)$140.00K
2021-12-31Reported-$28.27M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2021-09-30Reported-$21.67M(m)(m)(m)(m)$86.00K*-$13.89M*(m)$12.20M(m)$63.00K
2021-06-30Reported-$19.43M(m)(m)(m)(m)$85.00K*-$17.70M*(m)$11.35M(m)$9.00K
2021-03-31Reported-$13.57M(m)(m)(m)(m)$70.00K-$13.78M(m)$6.88M(m)$28.00K
2020-12-31Reported-$11.49M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2020-09-30Reported-$13.38M(m)(m)(m)(m)$11.00K*-$13.91M*(m)$6.88M(m)$82.00K
2020-06-30Reported-$17.59M(m)(m)(m)(m)(m)(m)(m)$6.72M(m)$43.00K

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported(m)-$179.04M(m)(m)(m)(m)-$157.24M(m)$118.44M(m)-$2.47M
2024-12-31Reported(m)-$178.21M(m)(m)(m)$0.00-$119.19M(m)$119.04M(m)$1.59M
2023-12-31Reported-$136.68M(m)(m)(m)(m)$66.00K-$97.38M(m)$87.52M(m)$780.00K
2022-12-31Reported-$110.07M(m)(m)(m)(m)$596.00K-$105.45M(m)$65.05M(m)$408.00K
2021-12-31Reported-$83.05M(m)(m)(m)(m)$334.00K-$67.75M(m)$44.03M(m)$199.00K
2020-12-31Reported-$51.28M(m)(m)(m)(m)$131.00K-$41.38M(m)$23.37M(m)$32.00K
2019-12-31Reported-$21.12M(m)(m)(m)(m)$165.00K-$17.81M(m)$12.56M(m)$15.00K

Similar stocks

Stock NameCountryMarket CapPE Ratio
ANI PHARMACEUTICALS INC (ANIP)United States$1.810B18.77
Septerna, Inc. (SEPN)United States$1.783B-63.01
Xencor Inc (XNCR)United States$1.776B-7.33
Zymeworks Inc. (ZYME)United States$1.902B-12.44
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74
Sarepta Therapeutics, Inc. (SRPT)United States$1.941B-13.89
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38
Biohaven Ltd. (BHVN)United States$1.990B-3.83
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82